REM-422
ARIA
Remix Therapeutics (merging with Passage Bio) · Phase 1/2 · Recruiting · Enrollment 125
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| REM-422 24 mg (RP2D), biomarker positive | R/M ACC, MYB biomarker positive at RP2D (n = 7) | 24 mg | Single arm | n/r | objective response rate: 43%, cutoff 01.07.2026, Abstract 6009 states 42% (3 of 7)disease control rate: 100%, ASCO 2026 |
| REM-422 12 mg or more, biomarker positive | biomarker-positive R/M ACC (n = 30) | 12 to 48 mg | Single arm | n/r | any target-lesion reduction: 70%, cutoff 01.07.2026target-lesion shrinkage of 20% or more: 47%, cutoff 01.07.2026 |
| REM-422 24 mg, safety | all patients at RP2D (n = 15) | 24 mg | Single arm | n/r | n/r |
| REM-422 Phase 2 confirmatory cohort | biomarker-positive ACC (40 to 50 planned) | 24 mg | Single arm | n/r | n/r |